Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donor Regulatory T-cells for Steroid-Refractory Chronic GVHD
NCT03683498Phase 1Completed
- Sponsor
- Fundación Pública Andaluza para la Gestión de la Investigación
- Start
- Sep 2018
- Primary completion
- Mar 2022
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in chronic graft-versus-host disease (cGVHD), sponsored by Fundación Pública Andaluza para la Gestión de la Investigación. Primary endpoint: Toxicity and maximum tolerated dose at 12 weeks. Started Sep 2018; status: completed.
02
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT03683498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03683498.